Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

Contributed by: Business Wire

Logo

Tags

Biotechnology

FDA

Pharmaceutical

Health

Dong-A ST CO., Ltd

More Like This

CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults